Sign in
TerminatedPhase 1

Functional and Structural Assessment of Endobronchial Valve Recipients Using Dynamic Hyperpolarized Xenon-129 MRI

Key facts

Who runs it
Xemed LLC
Where
Philadelphia, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 1
People taking part
27 people enrolled
Started
20 Oct 2023
Ended
11 Sept 2025
Type of study
Interventional
Treatments tested
  • MagniXene Hyperpolarized Xenon MRI
Record updated
30 September 2025
Why it stopped
Regulatory Compliance

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • COPD patients scheduled to receive endobronchial valve therapy
  • Patient is conscious, cooperative and agrees to return for scheduled visits and tests

Who cannot take part

  • Active drug or alcohol dependence
  • A language, communication, cognitive or behavioral impairment that might interfere with fully informed participation in the study
  • History of uncompensated organ failure (i.e. organ failure that is not stabilized through medical intervention), which will be assessed by the PI
  • Patients less than 18 years old
  • Patients known to be pregnant - a positive pregnancy test will be used to respectively exclude pregnant patients
  • Any known contraindication to MRI examination
  • Anyone with an implanted metal device
  • Inability to provide informed consent
  • Homelessness or other unstable living situation
  • Claustrophobia
  • Subjects weighting more than 300 pounds
  • Subjects with chest size larger than the bore of MRI machine from the study

Where in United States

  • Hospital of the University of PennsylvaniaPhiladelphia, United States

About the trial

What the trial wants to find out

This study proposes to use hyperpolarized xenon-129 Magnetic Resonance Imaging (MRI) to study lung function of COPD patients who will receive endobronchial valve (EBV) therapy as part of their clinical standard-of-care. Once inhaled, HP xenon can provide information to imagers regarding functionality across specific regions of the lungs through the assessment of the replacement of air during the normal breathing cycle, how much oxygen is in the airspaces, and if the normal spongy tissue structure has been compromised by lung disease. Pre- (baseline) and post-EBV (follow-up) lung function imaging with HPXe will potentially lead to be better understand disease progression and treatment mechanism.

The group in the trial

  • Hyperpolarized Xenon MRI assessment of lung function in endobronchial valve treated COPD patientsTreatment being tested

    Volunteer patients scheduled for receiving endobronchial valve treatment as part of clinical care will be imaged with hyperpolarized xenon prior and post EBV for assessing lung function and improvement.

    Treatment: MagniXene Hyperpolarized Xenon MRI

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
30 September 2025